Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-163

Here are three links to relevant "Herceptin ((trastuzumab) plus chemotherapy versus SOC chemotherapy alone in advanced HER-2 positive gastric cancer" studies:

Gastric Cancer. 2014; 17(1): 1–12.
Published online 2013 Apr 7. doi: 10.1007/s10120-013-0252-zPMCID: PMC3889288PMID: 23563986
HER2-positive gastric cancer
Narikazu Boku corresponding author
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889288/

Clinical Trial ReportOpen AccessPublished: 29 March 2019
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
Fernando Rivera, C. Romero, P. Jimenez-Fonseca, M. Izquierdo-Manuel, A. Salud, E. Martínez, M. Jorge, V. Arrazubi, J. C. Méndez, P. García-Alfonso, M. Reboredo, J. Barriuso, N. Muñoz-Unceta, R. Jimeno & C. López
Cancer Chemotherapy and Pharmacology volume 83, pages1175–1181 (2019)
https://link.springer.com/article/10.1007/s00280-019-03820-7#Tab2


ReviewOpen AccessPublished: 17 May 2019
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Dan Zhao, Samuel J. Klempner & Joseph Chao
Journal of Hematology & Oncology volume 12, Article number: 50 (2019)
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0737-2


The latter study may explain why IMU is introducing further HER-Vaxx Ph 2 trials as a way of differentiating itself from Herceptin ((trastuzumab) and addressing some of the challenges.

I note that some of the following statements in todays ASX announcement::

"Imugene’s MD & CEO Ms Leslie Chong said “We are encouraged by the PFS and anticipated
primary OS clinical data to commence three new HER-Vaxx trials, to be called NextHERIZON,
NeoHERIZON and NeuHERIZON, in early and late stage gastric cancer including combination
with PD-1 and PD-L1 checkpoint inhibitors. These studies will be conducted in the US,
Australia and South Korea.”

>>> Previous studies by other companies have been conducted in South Korea. There appears to be some difference in treatment outcomes between Asian and Western patients.

"The HERIZON Phase 2 trial, which has completed recruitment, is being conducted at multiple
sites across Eastern Europe and Indiawhere clinicians have difficulty accessing approved
antibody treatments such as Herceptin"


IMU's primary endpoint is overall survival (OS) data when it becomes available may also help to differentiate HER-Vaxx

GLTAHs